Plasmid DNA is surging as an ideal starting material for gene therapies and vaccine production. Using new market research, let’s look at key market drivers, vital roadblocks, regional analysis, and the leading players in the space.
- Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing
- FDA Adopts ICH Guidance On Assessing Nonclinical Biodistribution Of Gene Therapy Viral Vectors
- Best Practices For Raw Material And Supplier Management For Cell & Gene Therapy Manufacturing
- All You Need To Know About Contamination Control Strategies, Part 2
- Part 2: What You Should Expect from A High-Functioning CDMO
- Where Fly-Fishing Meets mRNA: The Art Of mRNA Immunogenicity
- Optimizing Digitalization To Accelerate Your R&D
- Let’s Explore Packaging For Aseptic Manufacturing
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Untouched Tumor Cell Isolation Improves NGS Analysis, Enrichment Of Cancer Stem Cells
Here, bulk tumor and isolated tumor cells were subjected to whole exome sequencing (WES) to assess the impact of non-tumor cell depletion on the sensitivity of downstream NGS analyses.
-
Improvements In Recovery, Reproducibility, And Matrix Effects With A Novel Solid Phase Extraction Sorbent
In this study we review a successful next generation reversed solid-phase extraction (SPE) product that produces cleaner extracts with simpler protocols and faster processing time.
-
Optimizing Accuracy Performance On A Beckman Coulter Biomek
Explore an approach for optimizing pipetting accuracy on a Beckman Coulter Biomek liquid handler using MVS® measurement information.
-
Capitalize On Regulatory Expertise To Simplify FDA Complexities
Get an overview of the global approval landscape, pathways to approval, including typical impediments to success, and the importance of formulating a robust clinical development program as made possible with the help of an experienced and well-resourced CRO.
-
BEH C18 Batch-To-Batch Robustness For The Analysis Of Rosuvastatin And Impurities
The main goal of this study is to investigate the long-term batch-to-batch reproducibility of 10 different lots of XBridge BEH C18 Columns. Discover the findings of this study.
-
Particulate Contamination Levels In Single-Use Systems
We investigate material adsorption of mRNA-encapsulated lipid nanoparticle (LNP) formulation comparing the Aramus fluoropolymer bag to commonly used glass vials and polypropylene (PP) cryotubes.
-
Method Migration Of Size-Exclusion And Ion- Exchange Methods For Monoclonal Antibody Analysis
Discover how combining this system with modern UHPLC columns could make data more accurately interpreted through greater efficiency, selectivity, and enhanced resolution.
-
Using Dual Dye Ratiometric Technology To Quantify The Impact Of Pipette Tip Type
Testing volume transfer performance can give good indicators of tip performance and reliability. When tip reliability is in question, assay results, in turn, could be in question as well.
-
Purification Of mRNA By Affinity Chromatography On CIMmultus® Oligo dT Column
Increasing demand for messenger RNA (mRNA) as therapeutic product requires efficient and scalable purification methods. In this application note a CIMmultus® Oligo dT, a monolithic stationary phase is used for purification of mRNA from a capping mix of Luc2 RNA. The large channels and convective mass transfer within the stationary phase eliminate shear forces and allow high flow rates, which leads to very short purification times and high recoveries.
-
Bacto CD Supreme FPM Consistently Supports Higher Growth And Plasmid Production In E. coli
Traditional microbial media for E. coli often contain animal-origin components and are complex. Stemmed from an overall industry drive to develop animal origin–free (AOF) and chemically defined (CD) media, Gibco™ Bacto™ CD Supreme Fermentation Production Medium (FPM) supports process flexibility and consistency in production. Read the results of a head-to-head comparison between Bacto CD Supreme FPM and Terrific Broth (TB), a traditional microbial medium.
NEWSLETTER ARCHIVE
- 06.01.23 -- What You Should Expect From A High-Functioning CDMO
- 05.31.23 -- Improving The Speed, Efficiency, And Outcome Of Your Project Through Fit-For-Purpose Quality Management
- 05.30.23 -- Accelerate Your Cell And Gene Therapy Research
- 05.30.23 -- FDA's Digital Health Tech Framework Addresses Challenges
- 05.25.23 -- The Potential Of Prime Editing

CELL AND GENE LIVE

To achieve commercial success, a developed process must be scalable and suitable for a manufacturing environment. The scaling strategy depends on the type of cell therapy. Check out our latest Cell & Gene Live - now available On-Demand.
Cell & Gene Live ArchiveCELL AND GENE CONTENT COLLECTIONS

While both allogeneic and autologous therapies use similar technologies common to the growth of cells, the scale is different. In this e-book from Cell & Gene, we've curated insightful editorial that concentrates on the advancements of both allogeneic and autologous therapies and how to manufacture them at scale.
More Content Collections